Skip to Main Content
Affiliates  AUGS | IUGA

Abstract Guidelines

All accepted abstracts will be published in a supplement of the International Urogynecology Journal (IUJ) and in a supplement of the Female Pelvic Medicine & Reconstructive Surgery (FPMRS) journal.

Late-Breaking Abstract Submission Guidelines

Submissions Open: June 14, 2019
Submission Deadline: July 15, 2019

Late-breaking abstract submissions are intended to allow for the timely presentation of high impact trials to AUGS-IUGA meeting attendees.  It is expected that these abstract submissions are from studies for which no preliminary data was available at the time of the abstract submission deadline (April 15, 2019).

This meeting feature is not a mechanism to update previously submitted preliminary data or to provide an opportunity for previously rejected abstracts to be revised and resubmitted for consideration.

Priority will be given (in the following order) to:

  • Results of phase III clinical trials
  • Results of phase II clinical trials
  • Extraordinary findings from a basic science investigation
  • Interim analyses of phase III trials that describe important secondary end points
  • Prospective multi-institution clinical trials

Submit Now


Who Is Eligible to Submit?
IUGA Members, AUGS Members and non-members are eligible to submit an abstract.

Work submitted for presentation at this meeting may not have been previously published or presented at another international meeting (for example ICS). Please do not submit case reports as they are not permitted and will not be reviewed.

Ethics/Institutional Review Board Approval of Research
Authors should submit a statement from the research ethics committee or institutional review board indicating approval of the research. If the study was not submitted to a research ethics committee or institutional review board, authors need to provide documentation to prove that not seeking review for the study was in accordance with the policy of your institution.

Accessing the Abstract Submission Site

  • The submission site will open on June 14, 2019.
  • There are no restrictions on the number of submissions you may submit or on the number of submissions you may present.
  • The deadline for electronic submissions for abstracts is July 15, 2019 at 11:59 PM ET.


All abstracts must be prepared in English.

Abstract Character Limit 

  • Title character limit: 250 characters, including spaces.
  • Body character limit: There is a limit of 3300 (including spaces) characters for the text of your submission. You will be advised of your character count usage throughout the submission process as you save and move to the next step.
  • Figures and Tables limit: You may add up to 2 figures and/or tables to your submission. Figures and tables will appear at the end of your abstract, both on the proof and for publication. Figures and tables cannot be placed within the text of the submission. Figures and tables will count for 560 characters each. For reference, the characters will be deducted from your total character-count once uploaded.

Abstract Title

  • Please make sure you double-check your title, as it will be published as submitted.
  • Use mixed case for title – do not use all caps or all lowercase. Do not put your title in quotation marks.
  • Titles may not exceed 250 characters.
  • Do not include trial group name in title of abstract.


  • Please consult with your co-authors on how they would like their names to appear. Please enter all authors in the order they should appear in the heading of the abstract. If you (the Contact Author) are not the Presenter on a submission, you will need to provide contact information on the Presenter.
  • All authors and co-authors must disclose any relevant financial relationship(s) at the time of submission.

Responsibilities of the Corresponding Author
The first author listed for each abstract serves as the corresponding author and as the primary contact for all correspondence regarding the abstract. The corresponding author is responsible for the following:

  • Ensuring that all authors have read the abstract and agreed to be co-authors.
  • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by AUGS/IUGA.
  • Obtaining all the conflict of interest disclosures.

Abstract Body

Omit all names and geographical references in the body of the abstract. Organize content in sections as follows:

  • Objective: describes the research objective
  • Methods: describes research methodology used
  • Results: summarizes evaluation, including outcome data
  • Conclusions: states the conclusions drawn from results

In case of violation the abstract will be rejected.


Disclose any 'relevant' financial relationships in accordance with the ACCME guidelines. The ACCME defines 'relevant' financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. List any financial interests, assistance, or relationships with companies, supporters, or commercial products related to the research (for example, ownership or partnership; research support; research grants; sponsors; stockholders, etc.). All listed authors/co-authors must complete a disclosure via the online abstract management system.

Presentation Type and Category

  • You will be asked to select the appropriate presentation type for your submission.
  • Select the appropriate category using the list provided:
    • Anatomy, Cadaver/Surgical
    • Anatomy, Imaging
    • Anorectal Disorders (Incontinence/Dysfunction/RV fistula/other
    • Basic Science POP (includes pathophysiology)
    • Basic Science UI/LUTS (includes pathophysiology)
    • Basic Science Other (e.g. pain, IC/PBS, anorectal, etc)
    • Conservative management POP
    • Conservative management UI/LUTS
    • Conservative management Other (e.g. pain, IC/PBS, voiding dysfunction)
    • Education (e.g. impact of training program on fellow/resident education)
    • Epidemiology/QOL PFD general, POP, UI/LUTS (including national databases)
    • Epidemiology/QOL Other (anorectal, IC/PBS, other)
    • Evaluation & Testing (including Imaging) POP
    • Evaluation & Testing (including Imaging, urodynamics) UI/LUTS
    • Evaluation & Testing other (e.g. pain, IC/PBS, voiding dysfunction, anorectal)
    • Health care delivery/Systems
    • Public Health/Population studies (not covered in Epidemiology)
    • Sexual function/sexual pain
    • Surgical POP (including QOL outcomes and complications)
    • Surgical UI/LUTS (including QOL outcomes and complications)
    • Surgical Other (fistula, novel approaches, etc)

Product Name Usage

  • For purposes of blind scoring, institutional names must be omitted whenever possible in the title and body of the abstract.
  • Authors are requested to avoid the use of commercially branded names.
  • If a specific device is only identifiable by its trade name, then this should appear in brackets after a generic description of the device.
  • Should it be necessary to use a trade name, then the trade names of all similar products or those within a class must be used.


  • Carefully check the proof of your abstract. Make sure all special characters and formatting are displaying properly in your proof.
  • If you find errors, return to the appropriate page by clicking on the page name in the left-hand menu to make your corrections.
  • You may return to the online submission site to revise your abstract until April 12, 2019 at 11:59 PM, ET.
  • After this date/time, the submission site will close and no additional changes/edits can be made.
  • If your abstract contains errors, you may opt to withdraw the abstract.
  • If you have not completed all required sections and details you will not be able to submit.
  • When all required information is entered, the "Conclude Submission" button will appear at the bottom of the "Confirmation" step.


  • After April 12, corresponding authors may submit a request to have an abstract withdrawn.
  • To withdraw a submitted abstract after the deadline, written notification must be sent to
  • This notification must include the title, authors and affiliations (as submitted), the control number, and the name, affiliation, phone, fax and email of the submitter.
  • We recommend using the summary page as part of this notification.
  • In order for an accepted abstract to be withdrawn and not appear in publications, notification must be received by Friday, August 30, 2019.
  • After this date, withdrawals are still accepted but abstracts may still appear in the joint meeting materials.

Need Help?

  • For technical assistance, regarding the abstract submission site, contact The Conference Exchange technical support at 401-334-0220 between 8:30 AM and 6:00 PM, ET, Monday through Friday, or by using the electronic feedback form.
  • For general abstract inquiries, email

Abstract Review

  • After the submission site closes, completed abstracts will be peer reviewed.
  • All abstracts will be blinded for review, meaning the abstracts will be reviewed without knowledge of the author/s, institution/s or disclosure information.

Abstract Acceptance/Rejection Notifications

  • You will be notified electronically of the acceptance/rejection of your abstract in the beginning of June.
  • This notification will include the date and time of session/presentation as well as type of presentation if accepted.
  • Only the corresponding author will be notified. It is the responsibility of the corresponding author to notify all co-authors.
  • If you do not receive your notification by June 20, you should contact

Video Submission Guidelines

Videos must be submitted electronically through the website.

If you are uploading a video abstract, select "Video Presentation" as your preferred presentation type on the "Title & Info" step. This will allow you to add a video on the "Upload Video" step.

The below criteria must be met for acceptance of video presentation.

  • Maximum duration: 8 minutes
  • File cannot be above the 500 MB
  • Videos must have English captions or narration
  • Please ensure that your videos protect patient anonymity and integrity.
  • Acceptable file formats are .mov, .mpg and mp4

PLEASE REMOVE ALL PRODUCT LOGOS/NAMES FROM VIDEO - if a video is submitted with the product name/logo included, the video will be disqualified from consideration.

Embargo Policy

All accepted abstracts submitted to the AUGS/IUGA Joint Scientific Meeting 2019 are embargoed until the first day of the meeting. The first author is responsible for conveying this information to all co-authors.

Special Characters and Formatting

If you copy and paste the title and/or body of your submission from your word processor, check to make sure that any special characters or formatting display as desired on the "Confirmation" step.

Content Validity and Fair Balance

Authors are required to prepare fair and balanced presentations that are objective and scientifically rigorous. All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection and analysis.

Use of Generic Versus Trade Names

Abstracts must use scientific or generic names when referring to products.


Accepted abstracts will only be considered for an award. AUGS and IUGA awards up to seven prizes.

Submit Now



IUGA Executive Office

14305 Southcross Dr, Suite 100
Burnsville, MN 55306, USA
P + 1 (952) 683-9037
Intl + 31 (0)75-647 63 65


American Urogynecologic Society

1100 Wayne Avenue, Suite 825
Silver Spring, MD 20910
P (301) 273-0570
F (301) 273-0778